<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28492790</article-id><article-id pub-id-type="pmc">5409251</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2016-0007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Effects of Low-Dose Recombinant Human Brain Natriuretic Peptide on
Anterior Myocardial Infarction Complicated by Cardiogenic Shock</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Yesheng</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>ZhiGang</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hang</surname><given-names>Jingyu</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Shixin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Jian</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Meng</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><aff id="aff1"><label>1</label>Heart Center, Shanghai Jiao Tong University Affiliated Sixth
People's Hospital, Shanghai, P.R. China.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Meng Wei, 600 Yishang Road, Shanghai
200233, China. E-mail: <email>mrweei_6h@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2017</year></pub-date><volume>32</volume><issue>2</issue><fpage>96</fpage><lpage>103</lpage><history><date date-type="received"><day>02</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p> The mortality due to cardiogenic shock complicating acute myocardial
infarction (AMI) is high even in patients with early revascularization.
Infusion of low dose recombinant human brain natriuretic peptide (rhBNP) at
the time of AMI is well tolerated and could improve cardiac function.</p></sec><sec><title>Objective</title><p> The objective of this study was to evaluate the hemodynamic effects of rhBNP
in AMI patients revascularized by emergency percutaneous coronary
intervention (PCI) who developed cardiogenic shock.</p></sec><sec><title>Methods</title><p> A total of 48 patients with acute ST segment elevation myocardial infarction
(STEMI) complicated by cardiogenic shock and whose hemodynamic status was
improved following emergency PCI were enrolled. Patients were randomly
assigned to rhBNP (n=25) and control (n=23) groups. In addition to standard
therapy, study group individuals received rhBNP by continuous infusion at
0.005 &#x000b5;g kg<sup>&#x02212;1</sup> min<sup>&#x02212;1</sup> for 72 hours.</p></sec><sec><title>Results</title><p> Baseline characteristics, medications, and peak of cardiac troponin I (cTnI)
were similar between both groups. rhBNP treatment resulted in consistently
improved pulmonary capillary wedge pressure (PCWP) compared to the control
group. Respectively, 7 and 9 patients died in experimental and control
groups. No drug-related serious adverse events occurred in either group.</p></sec><sec><title>Conclusion</title><p> When added to standard care in stable patients with cardiogenic shock
complicating anterior STEMI, low dose rhBNP improves PCWP and is well
tolerated.</p></sec></abstract><kwd-group><kwd>Myocardial Infarction. Shock</kwd><kwd>Cardiogenic. Natriuretic Peptide</kwd><kwd>Brain</kwd></kwd-group><funding-group><award-group><funding-source>Shanghai Municipal Health Bureau</funding-source><award-id>20124245</award-id></award-group><award-group><funding-source>Shanghai Jiao Tong University</funding-source><award-id>YG2013MS52</award-id></award-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>81300177</award-id></award-group><funding-statement>This study was supported by grants from the Shanghai Municipal
Health Bureau (20124245), Shanghai Jiao Tong University (YG2013MS52) and the
National Natural Science Foundation of China (81300177).</funding-statement></funding-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="8%" span="1"/><col width="40%" span="1"/><col width="4%" span="1"/><col width="8%" span="1"/><col width="40%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th colspan="2" align="left" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">ACEI</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Angiotensin converting
enzyme inhibitors</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">LMWH</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Low-molecular-weight
heparin</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">AMI</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Acute myocardial
infarction</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">LVADs</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Left ventricular assist
devices</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">ANOVA</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Analysis of
variance</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">LVEF</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">ANP</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Atrial natriuretic
peptide</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">PCI</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Percutaneous coronary
intervention</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">ARB</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Angiotensin receptor
blockers</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">MSOF</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Multiple systemic organ
failure</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">ASCEND-HF</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Acute Study of Clinical
Effectiveness of Nesiritide</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">NT-proBNP</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= N-terminal brain
natriuretic peptide</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">&#x000a0;and Decompensated Heart
Failure</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">PCWP</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Pulmonary capillary
wedge pressure</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">BNP</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= B type natriuretic
peptide</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">RAP</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Right atrial
pressure</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">CABG</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Coronary artery bypass
graft surgery</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">rhBNP</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Recombinant human brain
natriuretic peptide</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">cGMP</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Cyclic guanosine
monophosphate</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">SBP</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Systolic blood
pressure</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">CI</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Cardiac index</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">SOAP</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Sepsis occurrence in
acutely ill patients</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">cTnI</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Cardiac troponin I</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">SPSS</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Statistical Package for
the Social Sciences</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">ECG</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Eletrocardiograma</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">STEMI</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= ST segment elevation
myocardial infarction</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">eGFR</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Estimate glomerular
filtration rate</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">VMAC</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Vasodilation in the
Management of Acute</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">FDA</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= U. S. Food and Drug
Administration</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">Congestive Heart
Failure</td></tr><tr><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">IABP</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">= Intra-aortic balloon
pump</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">&#x000a0;</td><td style="background-color:#e6e7e8" align="left" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Cardiogenic shock complicates 6-10% of all ST segment elevation myocardial infarction
(STEMI) cases and remains a leading cause of death, with hospital mortality rates
approaching 50%<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.
Emergency revascularization with percutaneous coronary intervention (PCI) or
coronary artery bypass graft surgery (CABG) has been shown to improve long-term
survival of these patients<sup>[<xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Despite this progress,
cardiogenic shock continues to be associated with a high short-term mortality
rate<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.
Vasopressors and inotropes are used to improve the hemodynamic status, but the
information about comparative effective outcomes is limited; indeed, some of them
could induce decreased survival rate that may be associated with the deleterious
cellular effects of these drugs<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>B type natriuretic peptide (BNP), released due to altered chamber loading and myocyte
stretch, has been detected in acute myocardial infarction (AMI)<sup>[<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref>]</sup>. BNP can act via the natriuretic peptide receptor
A/guanylyl cyclase/cyclic guanosine monophosphate (cGMP) signaling pathway,
maintaining cardio-renal homeostasis through diuresis, natriuresis, vasodilation,
and inhibition of aldosterone synthesis and renin secretion under physiological and
pathological conditions<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Interestingly, exogenous BNP infusion may result in
coronary vasodilatation with reduced myocardial oxygen consumption<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>, enhanced myocardial
relaxation<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>, suppressed synthesis and release of
aldosterone<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>, induced vascular regeneration<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, delayed adrenergic
activation and inhibited cardiac fibroblast collagen synthesis<sup>[<xref rid="r15" ref-type="bibr">15</xref>-<xref rid="r17" ref-type="bibr">17</xref>]</sup>.</p><p>rhBNP (Recombinant human brain natriuretic peptide) was approved by the U. S. Food
and Drug Administration (FDA) for the management of acute decompensated heart
failure in 2001. Recently, a small study showed that rhBNP, given soon after AMI,
induces a trend towards favorable ventricular remodeling, but blood pressure was
lower with rhBNP over the first 8-12 hours of infusion without clinically
significant hypotension<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. Low-dose rhBNP administration could avoid hypotension
in patients with cardio-renal disease. Indeed, Brunner-La Rocca et
al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> have
reported that in humans withheart failure, low-dose rhBNP suppresses the adrenergic
outflow without hypotension. Chen et al.<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup> reported that 72 hours of infusion of low-dose
rhBNP at the time of anterior AMI is well tolerated, and may suppress aldosterone
and preserve ventricular function and structure in patients with anterior AMI.</p><p>There are currently no reports on low-dose rhBNP administration in patients with
cardiogenic shock complicating STEMI after successful early revascularization. We
proposed a pilot study to evaluate the safety and efficacy of low dose rhBNP in the
setting of STEMI complicated with cardiogenic shock. This study was designed to
evaluate the hemodynamic, neuro-hormonal, and renal effects of rhBNP given as a
72-hour infusion to AMI patients revascularized by emergency PCI who developed
cardiogenic shock, but were stable after appropriate medical intervention.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Patients</title><p>The study group included patients admitted to Shanghai 6<sup>th</sup> People's
Hospital, China, with cardiogenic shock complicating a first anterior AMI from
March 2009 to March 2013. Patients were eligible for the trial if they presented
with: (1) anterior STEMI complicated by cardiogenic shock; (2) successful early
revascularization performed with stable hemodynamic status in the 1<sup>st</sup>
hour post-intervention. Anterior STEMI was diagnosed by the following criteria:
prolonged chest pain &#x0003e;30 minutes; positive troponin I; ST-segment elevation 2
mv in two or more adjacent anterior precordial leads. A patient was considered
to be in cardiogenic shock if: (1) systolic blood pressure was less than 90 mmHg
for more than 30 minutes or catecholamine infusion was required to maintain a
systolic pressure above 90 mmHg; (2) clinical signs of pulmonary congestion were
present; or (3) there was evidence of impaired end organ perfusion. The
diagnosis of impaired end organ perfusion required at least one of the
following: altered mental status; cold, clammy skin and extremities; oliguria
with urine output of less than 30 ml per hour; serum lactate level higher than
2.0 mmol per liter. All patients got successful revascularization (emergency
PCI, TIMI grade 3 flow) and intra-aortic balloon pump (IABP) support within 24h
of onset of chest pain, were enrolled, and sent to Coronary Care Unit for
hemodynamic monitoring.</p><p>Exclusion criteria were: SBP &#x0003c; 90 mmHg within first hour post-intervention
although 12 mg/kg &#x000d7; min dopamine and 1:1 IABP supporting; pulmonary
capillary wedge pressure (PCWP) &#x0003c; 18 mmHg; acute inferior, posterior and
right ventricle myocardial infarction; previous history of myocardial
infarction; previous eletrocardiograma (ECG) suggesting an old myocardial
infarction; previous history of chronic heart failure or decreased left
ventricular ejection fraction (LVEF); hypertrophic cardiomyopathy;
hemodynamically significant mitral regurgitation; other hemodynamically
significant valvular or congenital heart diseases; estimate glomerular
filtration rate (eGFR) &#x0003c; 15 mL/min per 1.73 m<sup>2</sup>; previous known
intolerance history to rhBNP.</p><p>This was a randomized (sealed enveloped), open-label, parallel group study.
Patients were assigned to rhBNP or control group at a 1:1 ratio. The primary
endpoints were absolute changes in PCWP from baseline to 72 hours after
randomization compared to the control group. Secondary endpoints included
comparisons between rhBNP and control groups of the following hemodynamic and
clinical effects: cardiac index, in hospital mortality, 72 hours urine output,
and safety profile (renal function, hypotension). The trial protocol was
approved by the ethics committee of Shanghai 6<sup>th</sup> People's Hospital.
Documented informed consent was obtained from each patient or his/her
guardian.</p></sec><sec><title>Protocol</title><p>Each patient was monitored hemodynamically using a pulmonary artery Swan-Ganz
thermodilution catheter (bedside chest X-ray was done to check its position).
Arterial blood pressure was measured with IABP. Baseline heart rate, blood
pressure, right atrial pressure (RAP), PCWP and cardiac index (CI) were recorded
three times within a 5 minutes period using the bedside patient monitor.
Measurements were carried out by another research team member blinded to
treatment allocation. Additional measurements were performed 15 min and then 3,
24, 48 and 72h after starting drug administration. Echocardiography was
performed immediately after operation and read in random order with no patient
identifiers.</p><p>All the patients were given dopamine (3-12 mg/kg &#x000d7; min) after diagnosis of
cardiogenic shock, at dosage adjusted to achieve a satisfactory blood pressure
(SBP &#x0003c; 90 mmHg). Patients with stable blood pressure (SBP &#x0003c; 90 mmHg)
within 1 hour post-intervention were enrolled and randomized. In the rhBNP
group, rhBNP treatment was initiated after randomization for 72 hours with a
continuous infusion of 0.005 mg kg<sup>-1</sup>min<sup>-1</sup> without a
loading dose. The infusion dosage was decreased to 0.003 mg
kg<sup>-1</sup>min<sup>-1</sup> if SBP &#x0003c; 85 mmHg more than 20 minutes
despite dopamine titration. If symptomatic hypotension or systolic blood
pressure &#x0003c; 75 mmHg occurred, rhBNP infusion was interrupted for 30-60 minutes
and the dosage of dopamine increased. rhBNP treatment would restart at 0.003 mg
kg<sup>-1</sup>min<sup>-1</sup> when the dose-limiting event had resolved.
Infusion of rhBNP was discontinued for recurrent symptomatic hypotension;
sustained hypotension despite rhBNP dosage decrease to 0.003 mg
kg<sup>-1</sup>min<sup>-1</sup> or dopamine dosage increase to more than 12
mg kg<sup>-1</sup>min<sup>-1</sup>.</p><p>In addition to standard medical treatment, dobutamine and norepinephrine were
permitted for intractable hypotension and pump failure based on investigator's
clinical judgment. Statin, aspirin and clopidogrel were given before emergency
PCI. IIb/IIIa receptor antagonist (Tirofiban) was administered during the
procedure and next 24 hours according to the physician's judgment. Enoxaparin
was given from 6 to 72 hours after emergency PCI. Low dose of angiotensin
converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) as
well as beta-blocker therapy were started 24h after randomization if patients
tolerated. Blood for measurement of N-terminal brain natriuretic peptide
(NT-proBNP), BNP, cGMP and creatinine levels was drawn before the initiation of
IV rhBNP, then at 72 hours and 1 week after randomization.</p></sec><sec><title>Statistical Analysis</title><p>We postulated an expected change of PCWP as -3.8 mmHg from Vasodilation in the
Management of Acute Congestive Heart Failure (VMAC) study<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. We calculated that a
sample size of 21 patients would be needed in each group for a statistical power
of 80% at significance level of 0.05 (with a two-sided t-test).</p><p>Data were statistically processed and analyzed using the Statistical Package for
the Social Sciences (SPSS) 16.0 software package. Descriptive statistics were
presented as mean&#x000b1;standard deviation for continuous data and as
percentages for categorical data. Analyses of continuous data were performed by
two-sample t-test and categorical data by Chi-Square test. One way analysis of
variance (ANOVA) was used to evaluate the differences among groups after
treatment. The changes in renal function from baseline to after drug
administration were analyzed by paired t-test. <italic>P</italic> &#x0003c;0.05 was
considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 65 patients were screened, of whom 17 were excluded because of hypotension
(n=8), death before randomization (n=3), PCWP &#x0003c; 18 mmHg (n=3), eGFR &#x0003c; 15
mL/min per 1.73 m<sup>2</sup> (n=2) or significant mitral valve regurgitation
(n=1).</p><p>
<xref ref-type="table" rid="t1">Table 1</xref> summarizes the baseline
characteristics of patients, which were similar between both groups. Indeed, peak
cTnI, time to PCI, PCWP, CI and LVEF were comparable between the two groups at
baseline.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the patients.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">rhBNP (n=25)</th><th align="center" rowspan="1" colspan="1">Control (n=23)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age - years</td><td align="center" rowspan="1" colspan="1">64.9&#x000b1;12.6</td><td align="center" rowspan="1" colspan="1">64.1&#x000b1;10.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex - no. (%)</td><td align="center" rowspan="1" colspan="1">18 (72)</td><td align="center" rowspan="1" colspan="1">17 (74)</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index</td><td align="center" rowspan="1" colspan="1">23.5&#x000b1;2.8</td><td align="center" rowspan="1" colspan="1">24.2&#x000b1;2.7</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Cardiovascular risk factors - no. (%)</bold></td><td align="center" colspan="2" rowspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Smoking</td><td align="center" rowspan="1" colspan="1">14 (56%)</td><td align="center" rowspan="1" colspan="1">12 (52%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hypertension</td><td align="center" rowspan="1" colspan="1">12 (48%)</td><td align="center" rowspan="1" colspan="1">15 (65%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">9 (36%)</td><td align="center" rowspan="1" colspan="1">7 (30%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Time to PCI (h)</td><td align="center" rowspan="1" colspan="1">12.7&#x000b1;5.0</td><td align="center" rowspan="1" colspan="1">13.1&#x000b1;5.1</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Infarct-related artery - no. (%)</bold></td><td align="center" colspan="2" rowspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Left main</td><td align="center" rowspan="1" colspan="1">4 (16%)</td><td align="center" rowspan="1" colspan="1">4 (17%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Left anterior
descending</td><td align="center" rowspan="1" colspan="1">21 (84%)</td><td align="center" rowspan="1" colspan="1">18 (78%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Left circumflex</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1 (4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Multivessel disease - no. (%)</td><td align="center" rowspan="1" colspan="1">2.0&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">1.8&#x000b1;0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Peak cTnI (mg/L)</td><td align="center" rowspan="1" colspan="1">99.7&#x000b1;55.1</td><td align="center" rowspan="1" colspan="1">93.9&#x000b1;46.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">38.6&#x000b1;8.0</td><td align="center" rowspan="1" colspan="1">39.6&#x000b1;7.2</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR (mL/min - 1.73m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">65.4&#x000b1;28.6</td><td align="center" rowspan="1" colspan="1">67.2&#x000b1;33.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiac index (L/min - m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">1.7&#x000b1;0.2</td><td align="center" rowspan="1" colspan="1">1.7&#x000b1;0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">PCWP (mmHg)</td><td align="center" rowspan="1" colspan="1">27.2&#x000b1;4.1</td><td align="center" rowspan="1" colspan="1">27.0&#x000b1;4.2</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>Data are presented as mean value &#x000b1; SD</p><p>Body-mass index is the weight in kilograms divided by the square of the
height in meters.</p><p>eGFR = estimate glomerular filtration rate; PCI = percutaneous coronary
intervention; PCWP = pulmonary capillary wedge pressure;</p><p>rhBNP = recombinant human brain natriuretic peptide</p></fn></table-wrap-foot></table-wrap><p>
<xref ref-type="table" rid="t2">Table 2</xref> shows the clinical management in the
hospital. All the patients underwent successful PCI and IABP support. Rates of
noninvasive positive pressure ventilation were similar for both of them. Standard
medical therapy was used unless contraindicated. ACEI/ARB and beta-blockers were
used if tolerated and titrated gradually. Medical treatments in both groups were
similar; no significant differences were observed in average dopamine dosage as well
as dobutamine and epinephrine use between both groups.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Clinical management in hospital.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="30%" span="1"/><col width="30%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Management</th><th align="center" rowspan="1" colspan="1">rhBNP (n=25)</th><th align="center" rowspan="1" colspan="1">Control (n=23)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Emergency PCI - no. (%)</td><td align="center" rowspan="1" colspan="1">25 (100)</td><td align="center" rowspan="1" colspan="1">23 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">Stenting</td><td align="center" rowspan="1" colspan="1">25 (100)</td><td align="center" rowspan="1" colspan="1">23 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">Emergency CABG - no. (%)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Intra-aortic balloon pump - no. (%)</td><td align="center" rowspan="1" colspan="1">25 (100)</td><td align="center" rowspan="1" colspan="1">23 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">Left ventricular assist device - no. (%)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Noninvasive positive pressure ventilation - no.
(%)</td><td align="center" rowspan="1" colspan="1">12 (48)</td><td align="center" rowspan="1" colspan="1">12 (52)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Medication in hospital</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;rhBNP administration -
hours</td><td align="center" rowspan="1" colspan="1">60.4</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Dopamine- average dosage
(mg/kg&#x000d7;min)</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mean value &#x000b1;
SD</td><td align="center" rowspan="1" colspan="1">7.5&#x000b1;5.2</td><td align="center" rowspan="1" colspan="1">8.7&#x000b1;5.5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dobutamine - no.
(%)</td><td align="center" rowspan="1" colspan="1">2 (8)</td><td align="center" rowspan="1" colspan="1">3 (13)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Norepineprine - no.
(%)</td><td align="center" rowspan="1" colspan="1">3 (12)</td><td align="center" rowspan="1" colspan="1">2 (9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Diuretic - no. (%)</td><td align="center" rowspan="1" colspan="1">22 (88)</td><td align="center" rowspan="1" colspan="1">21 (91)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Beta-blocker - no.
(%)</td><td align="center" rowspan="1" colspan="1">20 (80)</td><td align="center" rowspan="1" colspan="1">16 (70)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;ACE inhibitor - no.
(%)</td><td align="center" rowspan="1" colspan="1">11 (44)</td><td align="center" rowspan="1" colspan="1">12 (52)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;ARB - no. (%)</td><td align="center" rowspan="1" colspan="1">3 (12)</td><td align="center" rowspan="1" colspan="1">4 (17)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Statins - no. (%)</td><td align="center" rowspan="1" colspan="1">22 (88)</td><td align="center" rowspan="1" colspan="1">21 (91)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Clopidogrel - no.
(%)</td><td align="center" rowspan="1" colspan="1">25 (100)</td><td align="center" rowspan="1" colspan="1">23 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Aspirine - no. (%)</td><td align="center" rowspan="1" colspan="1">23 (92)</td><td align="center" rowspan="1" colspan="1">20 (87)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;IIb/IIIa receptor
antagonist - no. (%)</td><td align="center" rowspan="1" colspan="1">10 (40)</td><td align="center" rowspan="1" colspan="1">11 (48)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;LMWH - no. (%)</td><td align="center" rowspan="1" colspan="1">25 (100)</td><td align="center" rowspan="1" colspan="1">22 (96)</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker;
CABG = coronary-artery bypass grafting; LMWH = lowmolecular- weight
heparin; PCI = percutaneous coronary intervention</p></fn></table-wrap-foot></table-wrap><p>A total of 16 patients died in hospital. In the rhBNP group, 5 patients died within
72h of randomization [pump failure (n=4); multiple systemic organ failure -
MSOF - (n=1)], and 1 patient died at each day 4 (cardiac rupture) and 10
(pump failure) after randomization. In the control group, 8 patients died within 72h
after randomization [pump failure (n=5); MSOF (n=2); ventricular fibrillation
(n=1) and 1 died at day 6 (pump failure). These findings indicated that there was no
significant difference in in-hospital mortality between the two groups (28.0 vs.
39.1%; P=0.305). No re-infarctions or cerebrovascular accidents were observed in
either group.</p><p>Hemodynamic characteristics at 3 and 72h after randomization were analyzed in live
patients (<xref ref-type="table" rid="t3">Table 3</xref>). After rhBNP infusion,
PCWP and RAP were significantly decreased compared to the control group; cardiac
index showed increasing trend in the rhBNP group, but the differences were not
statistically significant. No statistically significant differences were obtained
for heart rate, SBP and mean blood pressure between both groups. The dose of rhBNP
was reduced to 0.003 mg kg<sup>-1</sup>min<sup>-1</sup> in 3 patients because of
asymptomatic hypotension. In 2 patients of the study group, rhBNP infusion was
discontinued for symptomatic hypotension, which resolved with no clinical
consequences after infusion was stopped. The 72h urine volume after randomization
showed no statistically significant difference between these two groups (rhBNP
group, 2293 ml/d; control group, 2053 ml/d; P=0.11).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Changes of hemodynamic parameters (compare to baseline).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Hemodynamic parameters</th><th align="center" rowspan="1" colspan="1">rhBNP (n=20)</th><th align="center" rowspan="1" colspan="1">Control (n=15)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HR (bpm) baseline</td><td align="center" rowspan="1" colspan="1">96.7&#x000b1;11.3</td><td align="center" rowspan="1" colspan="1">99.1&#x000b1;15.8</td><td align="center" rowspan="1" colspan="1">0.601</td></tr><tr><td align="left" rowspan="1" colspan="1">HR (bpm) 72h</td><td align="center" rowspan="1" colspan="1">-14.0&#x000b1;8.8</td><td align="center" rowspan="1" colspan="1">-11.1&#x000b1;9.9</td><td align="center" rowspan="1" colspan="1">0.370</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg) baseline</td><td align="center" rowspan="1" colspan="1">105.8&#x000b1;11.6</td><td align="center" rowspan="1" colspan="1">102.7 &#x000b1; 9.4</td><td align="center" rowspan="1" colspan="1">0.399</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg) 72h</td><td align="center" rowspan="1" colspan="1">-1.9&#x000b1;11.8</td><td align="center" rowspan="1" colspan="1">+2.0&#x000b1;12.1</td><td align="center" rowspan="1" colspan="1">0.346</td></tr><tr><td align="left" rowspan="1" colspan="1">MBP (mmHg) baseline</td><td align="center" rowspan="1" colspan="1">78.1&#x000b1;6.0</td><td align="center" rowspan="1" colspan="1">78.8&#x000b1;5.6</td><td align="center" rowspan="1" colspan="1">0.732</td></tr><tr><td align="left" rowspan="1" colspan="1">MBP (mmHg) 72h</td><td align="center" rowspan="1" colspan="1">-0.9&#x000b1;7.1</td><td align="center" rowspan="1" colspan="1">+0.5&#x000b1;8.1</td><td align="center" rowspan="1" colspan="1">0.591</td></tr><tr><td align="left" rowspan="1" colspan="1">RAP (mmHg) baseline</td><td align="center" rowspan="1" colspan="1">15.0&#x000b1;1.7</td><td align="center" rowspan="1" colspan="1">14.6&#x000b1;1.6</td><td align="center" rowspan="1" colspan="1">0.482</td></tr><tr><td align="left" rowspan="1" colspan="1">RAP (mmHg) 3h</td><td align="center" rowspan="1" colspan="1">-2.2&#x000b1;0.6</td><td align="center" rowspan="1" colspan="1">-1.5&#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">0.015</td></tr><tr><td align="left" rowspan="1" colspan="1">RAP (mmHg) 72h</td><td align="center" rowspan="1" colspan="1">-4.9&#x000b1;1.6</td><td align="center" rowspan="1" colspan="1">-3.4&#x000b1;0.8</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">PCWP (mmHg) baseline</td><td align="center" rowspan="1" colspan="1">26.1&#x000b1;3.8</td><td align="center" rowspan="1" colspan="1">25.3&#x000b1;4.1</td><td align="center" rowspan="1" colspan="1">0.541</td></tr><tr><td align="left" rowspan="1" colspan="1">PCWP (mmHg) 3h</td><td align="center" rowspan="1" colspan="1">-5.5&#x000b1;2.6</td><td align="center" rowspan="1" colspan="1">-2.1&#x000b1;3.4</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">PCWP (mmHg) 72h</td><td align="center" rowspan="1" colspan="1">-9.3&#x000b1;3.6</td><td align="center" rowspan="1" colspan="1">-5.3&#x000b1;3.1</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">CI (L/min &#x000d7; m<sup>2</sup>) baseline</td><td align="center" rowspan="1" colspan="1">1.7&#x000b1;0.1</td><td align="center" rowspan="1" colspan="1">1.7&#x000b1;0.1</td><td align="center" rowspan="1" colspan="1">0.760</td></tr><tr><td align="left" rowspan="1" colspan="1">CI (L/min &#x000d7; m<sup>2</sup>) 3h</td><td align="center" rowspan="1" colspan="1">+0.1&#x000b1;0.1</td><td align="center" rowspan="1" colspan="1">0.0&#x000b1;0.1</td><td align="center" rowspan="1" colspan="1">0.122</td></tr><tr><td align="left" rowspan="1" colspan="1">CI (L/min &#x000d7; m<sup>2</sup>) 72h</td><td align="center" rowspan="1" colspan="1">+0.4&#x000b1;0.1</td><td align="center" rowspan="1" colspan="1">+0.3&#x000b1;0.2</td><td align="center" rowspan="1" colspan="1">0.079</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>Data are presented as mean value &#x000b1; SD.</p><p>CI = cardiac index; HR = heart rate; MBP = medium blood pressure; PCWP =
pulmonary capillary wedge pressure; RAP = right atrium pressure; SBP =
systolic blood pressure</p></fn></table-wrap-foot></table-wrap><p>As shown in <xref ref-type="table" rid="t4">Table 4</xref>, plasma BNP levels
increased from baseline after rhBNP infusion, and decreased when the infusion was
stopped. cGMP, a secondary messenger of BNP, increased in the rhBNP group compared
to control patients. NT-proBNP and eGFR levels were not statistically different
between the two groups. In addition, no statistically significant difference was
observed in eGFR after rhBNP infusion (68.3&#x000b1;25.2 vs. 64.8&#x000b1;19.7
P=0.401).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Changes of biomarkers and renal function.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Biomarkers</th><th align="center" rowspan="1" colspan="1">rhBNP (n=19)</th><th align="center" rowspan="1" colspan="1">Control (n=14)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NT-proBNP (pg/ml) baseline</td><td align="center" rowspan="1" colspan="1">6097.5&#x000b1;3932.7</td><td align="center" rowspan="1" colspan="1">5315.1&#x000b1;5657.1</td><td align="center" rowspan="1" colspan="1">0.642</td></tr><tr><td align="left" rowspan="1" colspan="1">NT-proBNP (pg/ml) 72h after randomization</td><td align="center" rowspan="1" colspan="1">3820.0&#x000b1;3446.1</td><td align="center" rowspan="1" colspan="1">4605.2&#x000b1;5063.1</td><td align="center" rowspan="1" colspan="1">0.599</td></tr><tr><td align="left" rowspan="1" colspan="1">NT-proBNP (pg/ml) 1 week after randomization</td><td align="center" rowspan="1" colspan="1">2951.4&#x000b1;2122.8</td><td align="center" rowspan="1" colspan="1">3640.6&#x000b1;3256.1</td><td align="center" rowspan="1" colspan="1">0.467</td></tr><tr><td align="left" rowspan="1" colspan="1">BNP (pg/ml) baseline</td><td align="center" rowspan="1" colspan="1">1186.2&#x000b1;738.1</td><td align="center" rowspan="1" colspan="1">1113.1&#x000b1;1089.4</td><td align="center" rowspan="1" colspan="1">0.820</td></tr><tr><td align="left" rowspan="1" colspan="1">BNP (pg/ml) 72h after randomization</td><td align="center" rowspan="1" colspan="1">1603.4&#x000b1;672.6</td><td align="center" rowspan="1" colspan="1">925.4&#x000b1;1090.2</td><td align="center" rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" rowspan="1" colspan="1">BNP (pg/ml) 1 week after randomization</td><td align="center" rowspan="1" colspan="1">609.0&#x000b1;464.0</td><td align="center" rowspan="1" colspan="1">670.0&#x000b1;711.2</td><td align="center" rowspan="1" colspan="1">0.767</td></tr><tr><td align="left" rowspan="1" colspan="1">cGMP (pmol/ml) baseline</td><td align="center" rowspan="1" colspan="1">5.0&#x000b1;1.0</td><td align="center" rowspan="1" colspan="1">4.8&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">0.587</td></tr><tr><td align="left" rowspan="1" colspan="1">cGMP (pmol/ml) 72h after randomization</td><td align="center" rowspan="1" colspan="1">6.2&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">4.1&#x000b1;0.8</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR (mL/min&#x000d7;1.73 m<sup>2</sup>) baseline</td><td align="center" rowspan="1" colspan="1">68.3&#x000b1;25.2</td><td align="center" rowspan="1" colspan="1">81.4&#x000b1;34.4</td><td align="center" rowspan="1" colspan="1">0.216</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR (mL/min&#x000d7;1.73 m<sup>2</sup>) 72h after
randomization</td><td align="center" rowspan="1" colspan="1">62.3&#x000b1;23.3</td><td align="center" rowspan="1" colspan="1">68.1&#x000b1;28.1</td><td align="center" rowspan="1" colspan="1">0.521</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR (mL/min&#x000d7;1.73 m<sup>2</sup>) 1 week after
randomization</td><td align="center" rowspan="1" colspan="1">64.8&#x000b1;19.6</td><td align="center" rowspan="1" colspan="1">69.4&#x000b1;24.5</td><td align="center" rowspan="1" colspan="1">0.558</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>Data are presented as mean value &#x000b1; SD (from patients alive on day
7).</p><p>BNP = brain natriuretic peptide; cGMP = cyclic guanosine monophosphate;
eGFR = estimate glomerular filtration rate; NT proBNP = N-terminal brain
natriuretic peptide</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Animal and clinical studies have shown that BNP infusion limits infarct size,
improves cardiac remodeling and protects cardiomyocytes<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r20" ref-type="bibr">20</xref>-<xref rid="r22" ref-type="bibr">22</xref>]</sup>. Recently, a large multicenter clinical
trial using atrial natriuretic peptide (ANP) at the time of myocardial reperfusion
with AMI was reported that ANP (carparitide) could reduce infarct size, improve
ejection fraction and decrease the rate of new-onset heart failure<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. Meta-analysis suggested
that ANP/BNP infusion might be effective in protecting left ventricular function in
patients with AMI<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>. Thus natriuretic peptides (ANP and BNP) seem to be
logical adjuncts to standard care for the treatment of AMI. Additionally, BNP has
proven effects on acute decompensated heart failure, and should not decrease blood
pressure at low dose<sup>[<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r15" ref-type="bibr">15</xref>]</sup>. Therefore, we
hypothesized that BNP would be safe and effective for the treatment of STEMI
patients with cardiogenic shock. In this study, 48 patients with cardiogenic shock
complicating anterior STEMI, successful emergency PCI, and stable hemodynamic status
post intervention were enrolled. The major findings of this study are: (1) in
comparison with controls, administration of low-dose rhBNP for 72 hours is
associated with PCWP reduction; (2) low dose rhBNP treatment is unlikely to be
limited by hypotension in this clinical setting; (3) low dose rhBNP does not
significantly affect the renal function. Patients with STEMI complicated by
cardiogenic shock can benefit from the hemodynamic effects of rhBNP. On the other
hand, the long-term benefits of remodeling inhibition and cardio-protection need to
be confirmed by further studies. Mortality in this study was lower than what
reported for the SHOCK trial<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. In this work, patients who remained unstable after
emergency PCI were excluded,which may explain the discrepancy.</p><p>In the American College of Cardiology/American Heart Association and European Society
of Cardiology guidelines for STEMI, emergency revascularization by PCI or CABG for
the cardiogenic shock complicating AMI is given a class IB
recommendation<sup>[<xref rid="r25" ref-type="bibr">25</xref>-<xref rid="r26" ref-type="bibr">26</xref>]</sup>. In our hospital,
emergency PCI is the first choice for these patients. IABP was the most widely used
form of mechanical hemodynamic support in this clinical setting at the time of the
present trial. In the current U.S. and European guidelines, IABP in the treatment of
cardiogenic shock is still given IIa and IIb recommendations, respectively, although
recent clinical trials showed IABP use does not significantly reduce the 30-day
mortality rate in these patients<sup>[<xref rid="r25" ref-type="bibr">25</xref>-<xref rid="r28" ref-type="bibr">28</xref>]</sup>.
Mechanical left ventricular assist devices (LVADs) have been used in cardiogenic
shock patients not responding to standard therapy, but evidence regarding their
benefits is limited. In this study, all patients were submitted to emergency PCI and
IABP support, and no LVADs were used. The Sepsis Occurrence in Acutely Ill Patients
(SOAP) II study was published during the early phase of this trial, with a subgroup
analysis showing that dopamine, as compared with norepinephrine, was associated with
increased mortality rate at 28 days in patients with cardiogenic
shock<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>.
However, dopamine is still given a IIa recommendation for AMI patients with CS in
the current European Society of Cardiology STEMI guideline<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>. Here, norepinephrine and
dobutamine were permitted for intractable hypotension and pump failure. All study
patients were treated by the same medical team, to limit biases.</p><p>The effect of rhBNP on renal function is controversial. A meta-analysis showed that
standard rhBNP dose (0.01 mg kg<sup>-1</sup>min<sup>-1</sup>) might be detrimental
to renal function in patients with acute decompensated heart
failure<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>;
meanwhile, the multicenter randomized control trial Acute Study of Clinical
Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) confirmed
its renal safety<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>. Recently, a small study reported that low-dose rhBNP
improves renal function in heart failure patients following AMI<sup>[<xref rid="r32" ref-type="bibr">32</xref>]</sup>. We demonstrated herein
that renal function before and after treatment was similar between both groups.</p><p>BNP is a biologically active hormone affecting diuresis and natriuresis. However,
increased urine output with physiological and common pharmacological doses of rhBNP
has been proven only in normal individuals. The ASCEND-HF trial<sup>[<xref rid="r33" ref-type="bibr">33</xref>]</sup> showed no evidence that
nesiritide increases urine output in patients with acute decompensated heart
failure. Here, we found no evidence that rhBNP increases urine output in the
cardiogenic shock patients assessed.</p><p>Some small scale clinical trials suggested rhBNP infusion might protect left
ventricular function in patients with AMI, but there is no randomized clinical trial
which with large sample on these patients<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>. Based on our results, further clinical
trial could be planned on rhBNP treatment for AMI patients with or without
cardiogenic shock.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>When added to standard care in stable patients with cardiogenic shock complicating
anterior STEMI, low dose of rhBNP improves PCWP and is well tolerated.</p></sec><sec><title>LIMITATION</title><p>This was a small open control randomized pilot study. There was no clinical data for
PCWP changes after 72h infusion of low dose rhBNP, so we postulated an expected PCWP
change of -3.8 mmHg as shown in the VMAC study, which was designed with 3 hours
rhBNP infusion at 0.01 mg kg<sup>-1</sup>min<sup>-1</sup> after randomization.
Further adequately powered trials are needed to test the short and long-term
benefits of rhBNP infusion in this clinical setting.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">YP</td><td align="left" valign="top" rowspan="1" colspan="1">Conception and design study; realization
of operations</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;</td><td align="left" valign="top" rowspan="1" colspan="1">and/or trials; analysis and/or data
interpretation;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;</td><td align="left" valign="top" rowspan="1" colspan="1">statistical analysis; manuscript redaction
or critical review of its content; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ZGL</td><td align="left" valign="top" rowspan="1" colspan="1">Final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JH</td><td align="left" valign="top" rowspan="1" colspan="1">Manuscript redaction or critical review of
its content; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SM</td><td align="left" valign="top" rowspan="1" colspan="1">Realization of operations and/or trials;
final manuscript approval </td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JM</td><td align="left" valign="top" rowspan="1" colspan="1">Statistical analysis; final manuscript
approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MW</td><td align="left" valign="top" rowspan="1" colspan="1">Final manuscript approval</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Heart Center, Shanghai Jiao Tong University
Affiliated Sixth People's Hospital, Shanghai, P.R. China.</p></fn><fn fn-type="financial-disclosure"><p>This study was supported by grants from the Shanghai Municipal Health Bureau
(20124245), Shanghai Jiao Tong University (YG2013MS52) and the National Natural
Science Foundation of China (81300177).</p></fn></fn-group><ack><title>ACKOWLEDGMENTS</title><p>The authors wish to thank Nicole Shan for expert statistical assistance, as well as
the co-investigators and staff at their respective institutions.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>RJ</given-names></name><name><surname>Spencer</surname><given-names>FA</given-names></name><name><surname>Gore</surname><given-names>JM</given-names></name><name><surname>Lessard</surname><given-names>D</given-names></name><name><surname>Yarzebski</surname><given-names>J</given-names></name></person-group><article-title>Thirty-year trends (1975 to 2005) in the magnitude of, management
of, and hospital death rates associated with cardiogenic shock in patients
with acute myocardial infarction: a population-based
perspective</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>9</issue><fpage>1211</fpage><lpage>1219</lpage><pub-id pub-id-type="pmid">19237658</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochman</surname><given-names>JS</given-names></name><name><surname>Sleeper</surname><given-names>LA</given-names></name><name><surname>Webb</surname><given-names>JG</given-names></name><name><surname>Sanborn</surname><given-names>TA</given-names></name><name><surname>White</surname><given-names>HD</given-names></name><name><surname>Talley</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Early revascularization in acute myocardial infarction
complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently
Revascularize Occluded Coronaries for Cardiogenic Shock</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><issue>9</issue><fpage>625</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">10460813</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzavik</surname><given-names>V</given-names></name><name><surname>Sleeper</surname><given-names>LA</given-names></name><name><surname>Cocke</surname><given-names>TP</given-names></name><name><surname>Moscucci</surname><given-names>M</given-names></name><name><surname>Saucedo</surname><given-names>J</given-names></name><name><surname>Hosat</surname><given-names>S</given-names></name><etal/></person-group><article-title>Early revascularization is associated with improved survival in
elderly patients with acute myocardial infarction complicated by cardiogenic
shock: a report from the SHOCK Trial Registry</article-title><source>Eur Heart J</source><year>2003</year><volume>24</volume><issue>9</issue><fpage>828</fpage><lpage>837</lpage><pub-id pub-id-type="pmid">12727150</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spence</surname><given-names>N</given-names></name><name><surname>Abbott</surname><given-names>JD</given-names></name></person-group><article-title>Coronary revascularization in cardiogenic shock</article-title><source>Curr Treat Options Cardiovasc Med</source><year>2016</year><volume>18</volume><issue>1</issue><fpage>1</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">26706849</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carnendran</surname><given-names>L</given-names></name><name><surname>Abboud</surname><given-names>R</given-names></name><name><surname>Sleeper</surname><given-names>LA</given-names></name><name><surname>Gurunathan</surname><given-names>R</given-names></name><name><surname>Webb</surname><given-names>JG</given-names></name><name><surname>Menon</surname><given-names>V</given-names></name><etal/></person-group><article-title>Trends in cardiogenic shock: report from the SHOCK Study. The
SHould we emergently revascularize Occluded Coronaries for cardiogenic
shocK?</article-title><source>Eur Heart J</source><year>2001</year><volume>22</volume><issue>6</issue><fpage>472</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">11237542</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thackray</surname><given-names>S</given-names></name><name><surname>Easthaugh</surname><given-names>J</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name><name><surname>Cleland</surname><given-names>JG</given-names></name></person-group><article-title>The effectiveness and relative effectiveness of intravenous
inotropic drugs acting through the adrenergic pathway in patients with heart
failure-a meta-regression analysis</article-title><source>Eur J Heart Fail</source><year>2002</year><volume>4</volume><issue>4</issue><fpage>515</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">12167393</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>CT</given-names></name><name><surname>Wang</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>DY</given-names></name><name><surname>Tsai</surname><given-names>ML</given-names></name><name><surname>Lin</surname><given-names>YS</given-names></name><name><surname>Cherng</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Benefits of intraaortic balloon support for myocardial infarction
patients in severe cardiogenic shock undergoing coronary
revascularization</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><issue>8</issue><elocation-id>e0160070</elocation-id><pub-id pub-id-type="pmid">27483439</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baxter</surname><given-names>GF</given-names></name></person-group><article-title>The natriuretic peptides</article-title><source>Basic Res Cardiol</source><year>2004</year><volume>99</volume><issue>2</issue><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">14963664</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hama</surname><given-names>N</given-names></name><name><surname>Itoh</surname><given-names>H</given-names></name><name><surname>Shirakami</surname><given-names>G</given-names></name><name><surname>Nakagawa</surname><given-names>O</given-names></name><name><surname>Suga</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Rapid ventricular induction of brain natriuretic peptide gene
expression in experimental acute myocardial infarction</article-title><source>Circulation</source><year>1995</year><volume>92</volume><issue>6</issue><fpage>1558</fpage><lpage>1564</lpage><pub-id pub-id-type="pmid">7664440</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishikimi</surname><given-names>T</given-names></name><name><surname>Maeda</surname><given-names>N</given-names></name><name><surname>Matsuoka</surname><given-names>H</given-names></name></person-group><article-title>The role of natriuretic peptides in
cardioprotection</article-title><source>Cardiovasc Res</source><year>2006</year><volume>69</volume><issue>2</issue><fpage>318</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">16289003</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaels</surname><given-names>AD</given-names></name><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Madden</surname><given-names>JA</given-names></name><name><surname>Chatterjee</surname><given-names>K</given-names></name></person-group><article-title>Effects of intravenous nesiritide on human coronary vasomotor
regulation and myocardial oxygen uptake</article-title><source>Circulation</source><year>2003</year><volume>107</volume><issue>21</issue><fpage>2697</fpage><lpage>2701</lpage><pub-id pub-id-type="pmid">12742984</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lainchbury</surname><given-names>JG</given-names></name><name><surname>Burnett</surname><given-names>JC Jr</given-names></name><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Redfield</surname><given-names>MM</given-names></name></person-group><article-title>Effects of natriuretic peptides on load and myocardial function
in normal and heart failure dogs</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2000</year><volume>278</volume><issue>1</issue><fpage>H33</fpage><lpage>H40</lpage><pub-id pub-id-type="pmid">10644581</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HH</given-names></name><name><surname>Martin</surname><given-names>FL</given-names></name><name><surname>Gibbons</surname><given-names>RJ</given-names></name><name><surname>Schirger</surname><given-names>JA</given-names></name><name><surname>Wright</surname><given-names>RS</given-names></name><name><surname>Schears</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Low-dose nesiritide in human anterior myocardial infarction
suppresses aldosterone and preserves ventricular function and structure: a
proof of concept study</article-title><source>Heart</source><year>2009</year><volume>95</volume><issue>16</issue><fpage>1315</fpage><lpage>1319</lpage><pub-id pub-id-type="pmid">19447837</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamahara</surname><given-names>K</given-names></name><name><surname>Itoh</surname><given-names>H</given-names></name><name><surname>Chun</surname><given-names>TH</given-names></name><name><surname>Ogawa</surname><given-names>Y</given-names></name><name><surname>Yamashita</surname><given-names>J</given-names></name><name><surname>Sawada</surname><given-names>N</given-names></name><etal/></person-group><article-title>Significance and therapeutic potential of the natriuretic
peptides/cGMP/ cGMP-dependent protein kinase pathway in vascular
regeneration</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><issue>6</issue><fpage>3404</fpage><lpage>3409</lpage><pub-id pub-id-type="pmid">12621153</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner-La Rocca</surname><given-names>HP</given-names></name><name><surname>Kaye</surname><given-names>DM</given-names></name><name><surname>Woods</surname><given-names>RL</given-names></name><name><surname>Hastings</surname><given-names>J</given-names></name><name><surname>Esler</surname><given-names>MD</given-names></name></person-group><article-title>Effects of intravenous brain natriuretic peptide on regional
sympathetic activity in patients with chronic heart failure as compared with
healthy control subjects</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>37</volume><issue>5</issue><fpage>1221</fpage><lpage>1227</lpage><pub-id pub-id-type="pmid">11300426</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Xin</surname><given-names>P</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Therapeutic effects of continuous infusion of brain natriuretic
peptides on postmyocardial infarction ventricular remodeling in
rats</article-title><source>Arch Cardiovasc Dis</source><year>2011</year><volume>104</volume><issue>1</issue><fpage>17</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">21276574</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuruda</surname><given-names>T</given-names></name><name><surname>Boerrigter</surname><given-names>G</given-names></name><name><surname>Huntley</surname><given-names>BK</given-names></name><name><surname>Noser</surname><given-names>JA</given-names></name><name><surname>Cataliotti</surname><given-names>A</given-names></name><name><surname>Costello-Boerrigter</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Brain natriuretic peptide is produced in cardiac fibroblasts and
induces matrix metalloproteinases</article-title><source>Circ Res</source><year>2002</year><volume>91</volume><issue>12</issue><fpage>1127</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">12480813</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillock</surname><given-names>RJ</given-names></name><name><surname>Frampton</surname><given-names>CM</given-names></name><name><surname>Yandle</surname><given-names>TG</given-names></name><name><surname>Troughton</surname><given-names>RW</given-names></name><name><surname>Lainchbury</surname><given-names>JG</given-names></name><name><surname>Richards</surname><given-names>AM</given-names></name></person-group><article-title>B-type natriuretic peptide infusions in acute myocardial
infarction</article-title><source>Heart</source><year>2008</year><volume>94</volume><issue>5</issue><fpage>617</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">17639095</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Publication Committee for the VMAC Investigators (Vasodilatation in
the Management of Acute CHF)</collab></person-group><article-title>Intravenous nesiritide vs nitroglycerin for treatment of
decompensated congestive heart failure: a randomized controlled
trial</article-title><source>JAMA</source><year>2002</year><volume>287</volume><issue>12</issue><fpage>1531</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">11911755</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Souza</surname><given-names>SP</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Heusch</surname><given-names>G</given-names></name><name><surname>Onody</surname><given-names>A</given-names></name><etal/></person-group><article-title>B-type natriuretic peptide limits infarct size in rat isolated
hearts via KATP channel opening</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2003</year><volume>284</volume><issue>5</issue><fpage>H1592</fpage><lpage>H1600</lpage><pub-id pub-id-type="pmid">12521930</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliver</surname><given-names>PM</given-names></name><name><surname>Fox</surname><given-names>JE</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Rockman</surname><given-names>HA</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Reddick</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Hypertension, cardiac hypertrophy, and sudden death in mice
lacking natriuretic peptide receptor A</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><issue>26</issue><fpage>14730</fpage><lpage>14735</lpage><pub-id pub-id-type="pmid">9405681</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokudome</surname><given-names>T</given-names></name><name><surname>Horio</surname><given-names>T</given-names></name><name><surname>Kishimoto</surname><given-names>I</given-names></name><name><surname>Soeki</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Kawano</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Calcineurin-nuclear factor of activated T cells pathway-dependent
cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for
atrial and brain natriuretic peptides</article-title><source>Circulation</source><year>2005</year><volume>111</volume><issue>23</issue><fpage>3095</fpage><lpage>3104</lpage><pub-id pub-id-type="pmid">15939815</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitakaze</surname><given-names>M</given-names></name><name><surname>Asakura</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Shintani</surname><given-names>Y</given-names></name><name><surname>Asanuma</surname><given-names>H</given-names></name><name><surname>Hamasaki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Human atrial natriuretic peptide and nicorandil as adjuncts to
reperfusion treatment for acute myocardial infarction (J-WIND): two
randomised trials</article-title><source>Lancet</source><year>2007</year><volume>370</volume><issue>9597</issue><fpage>1483</fpage><lpage>1493</lpage><pub-id pub-id-type="pmid">17964349</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyu</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Ge</surname><given-names>H</given-names></name><etal/></person-group><article-title>Natriuretic peptides as an adjunctive treatment for acute
myocardial infarction: insights from the meta-analysis of 1,389 patients
from 20 trials</article-title><source>Int Heart J</source><year>2014</year><volume>55</volume><issue>1</issue><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">24463927</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Gara</surname><given-names>PT</given-names></name><name><surname>Kushner</surname><given-names>FG</given-names></name><name><surname>Ascheim</surname><given-names>DD</given-names></name><name><surname>Casey</surname><given-names>DE Jr</given-names></name><name><surname>Chung</surname><given-names>MK</given-names></name><name><surname>Lemos</surname><given-names>JA de</given-names></name><etal/><collab>American College of Cardiology Foundation</collab><collab>American Heart Association Task Force on Practice
Guidelines</collab></person-group><article-title>2013 ACCF/AHA guideline for the management of ST-elevation
myocardial infarction: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines</article-title><source>Circulation</source><year>2013</year><volume>127</volume><issue>4</issue><fpage>e362</fpage><lpage>e425</lpage><pub-id pub-id-type="pmid">23247304</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Task Force on the management of ST-segment elevation acute
myocardial infarction of the European Society of Cardiology
(ESC)</collab><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>James</surname><given-names>SK</given-names></name><name><surname>Atar</surname><given-names>D</given-names></name><name><surname>Badano</surname><given-names>LP</given-names></name><name><surname>Bl&#x000f6;mstrom-Lundqvist</surname><given-names>C</given-names></name><name><surname>Borger</surname><given-names>MA</given-names></name></person-group><article-title>ESC Guidelines for the management of acute myocardial infarction
in patients presenting with ST-segment elevation</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><issue>20</issue><fpage>2569</fpage><lpage>2619</lpage><pub-id pub-id-type="pmid">22922416</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiele</surname><given-names>H</given-names></name><name><surname>Zeymer</surname><given-names>U</given-names></name><name><surname>Werdan</surname><given-names>K</given-names></name></person-group><article-title>Intraaortic balloon support for cardiogenic shock</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><issue>1</issue><fpage>81</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">23281982</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nativi-Nicolau</surname><given-names>J</given-names></name><name><surname>Selzman</surname><given-names>CH</given-names></name><name><surname>Fang</surname><given-names>JC</given-names></name><name><surname>Stenhlik</surname><given-names>J</given-names></name></person-group><article-title>Pharmacologic therapies for acute cardiogenic
shock</article-title><source>Curr Opin Cardiol</source><year>2014</year><volume>29</volume><issue>3</issue><fpage>250</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">24686400</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Backer</surname><given-names>D</given-names></name><name><surname>Biston</surname><given-names>P</given-names></name><name><surname>Devriendt</surname><given-names>J</given-names></name><name><surname>Madl</surname><given-names>C</given-names></name><name><surname>Chochrad</surname><given-names>D</given-names></name><name><surname>Aldecoa</surname><given-names>C</given-names></name><etal/><collab>SOAP II Investigators</collab></person-group><article-title>Comparison of dopamine and norepinephrine in the treatment of
shock</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>9</issue><fpage>779</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">20200382</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sackner-Bernstein</surname><given-names>JD</given-names></name><name><surname>Skopicki</surname><given-names>HA</given-names></name><name><surname>Aaronson</surname><given-names>KD</given-names></name></person-group><article-title>Risk of worsening renal function with nesiritide in patients with
acutely decompensated heart failure</article-title><source>Circulation</source><year>2005</year><volume>111</volume><issue>12</issue><fpage>1487</fpage><lpage>1491</lpage><pub-id pub-id-type="pmid">15781736</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dandamudi</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>HH</given-names></name></person-group><article-title>The ASCEND-HF trial: an acute study of clinical effectiveness of
nesiritide and decompensated heart failure</article-title><source>Expert Rev Cardiovasc Ther</source><year>2012</year><volume>10</volume><issue>5</issue><fpage>557</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">22651831</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>TG</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>JY</given-names></name><name><surname>Wang</surname><given-names>LX</given-names></name></person-group><article-title>Low-dose nesiritide improves renal function in heart failure
patients following acute myocardial infarction</article-title><source>Heart Vessels</source><year>2010</year><volume>25</volume><issue>2</issue><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">20339970</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname><given-names>SS</given-names></name><name><surname>Stebbins</surname><given-names>A</given-names></name><name><surname>Voors</surname><given-names>AA</given-names></name><name><surname>Hasselblad</surname><given-names>V</given-names></name><name><surname>Ezekowitz</surname><given-names>JA</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Effects of nesiritide and predictors of urine output in acute
decompensated heart failure: results from ASCEND-HF (acute study of clinical
effectiveness of nesiritide and decompensated heart failure)</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>62</volume><issue>13</issue><fpage>1177</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">23747790</pub-id></element-citation></ref></ref-list></back></article>